The 10-day moving average for LGND crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 59 cases where LGND's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
LGND moved above its 50-day moving average on September 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where LGND advanced for three days, in 263 of 343 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The 10-day RSI Indicator for LGND moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 31 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LGND as a result. In 65 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for LGND turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 37 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
LGND broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LGND entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. LGND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.472) is normal, around the industry mean (26.782). P/E Ratio (32.344) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (1.267) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (20.325) is also within normal values, averaging (437.542).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
XBI saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 83 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
XBI moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XBI crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XBI entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 297 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
LGND | ||
|---|---|---|
OUTLOOK RATING 1..100 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 5 | |
SMR RATING 1..100 | 44 | |
PRICE GROWTH RATING 1..100 | 39 | |
P/E GROWTH RATING 1..100 | 97 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| LGND | XBI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 69% | N/A |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 77% | N/A |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 90% |
| Advances ODDS (%) | 5 days ago 77% | 17 days ago 90% |
| Declines ODDS (%) | 3 days ago 68% | 3 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 70% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 71% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LGND’s FA Score shows that 1 FA rating(s) are green while .
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LGND’s TA Score shows that 4 TA indicator(s) are bullish.
LGND (@Biotechnology) experienced а +1.19% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.28%. For the same industry, the average monthly price growth was -17.87%, and the average quarterly price growth was -21.14%.
LGND is expected to report earnings on Nov 05, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FEP | 56.53 | 0.68 | +1.22% |
| First Trust Europe AlphaDEX Fund (FEP) | |||
| GDV | 28.52 | 0.27 | +0.96% |
| Gabelli Dividend & Income Trust (The) | |||
| EJAN | 36.88 | -0.10 | -0.28% |
| Innovator Emerging Markets Power Buffer ETF January (EJAN) | |||
| TFFI | 21.30 | -0.21 | -0.96% |
| Chesapeake Trend-Following Fixed Income ETF | |||
| QQXL | 56.25 | -0.58 | -1.01% |
| ProShares Ultra QQQ Top 30 (QQXL) | |||
A.I.dvisor indicates that over the last year, LGND has been loosely correlated with AXON. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if LGND jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To LGND | 1D Price Change % | ||
|---|---|---|---|---|
| LGND | 100% | +1.19% | ||
| AXON - LGND | 49% Loosely correlated | +2.15% | ||
| VCYT - LGND | 41% Loosely correlated | +2.02% | ||
| TVTX - LGND | 41% Loosely correlated | -0.90% | ||
| ABCL - LGND | 37% Loosely correlated | +2.51% | ||
| TRDA - LGND | 36% Loosely correlated | +5.05% | ||
More | ||||